Guide to information on human medicines evaluated by European Medicines Agency: what the Agency publishes and when
HMPC: overview of assessment work - priority list
Procedural advice for orphan medicinal product designation: Guidance for sponsors
Guidance notes on the use of Veterinary Dictionary for Drug Regulatory Activities (VeDDRA) terminology for reporting suspected adverse events in animals and humans - Rev.17
Human medicines European public assessment report (EPAR): Ilumetri, tildrakizumab, Date of authorisation: 17/09/2018, Revision: 15, Status: Authorised
Clinical Trials Information System (CTIS) Bitesize talk: Redesign of the CTIS training material for sponsor users, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 9 July 2025, 15:30 (CEST) to 9 July 2025, 17:00 (CEST)
Human medicines European public assessment report (EPAR): Otezla, apremilast, Date of authorisation: 15/01/2015, Revision: 24, Status: Authorised
PSUSA/00002291/202412
PSUSA/00003179/202411
PSUSA/00002443/202412